A Director at Foundation Medicine (NASDAQ: FMI) is Selling Shares

Today, a Director at Foundation Medicine (NASDAQ: FMI), Michael Pellini, sold shares of FMI for $1.77M.

Following Michael Pellini’s last FMI Sell transaction on August 10, 2017, the stock climbed by 19.6%. In addition to Michael Pellini, 4 other FMI executives reported Sell trades in the last month.

Based on Foundation Medicine’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $42.66 million and GAAP net loss of $32.64 million. In comparison, last year the company earned revenue of $29.43 million and had a GAAP net loss of $31.28 million. The company has a one-year high of $70.75 and a one-year low of $17.10. The Company has a book value per share of 33.2305.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Foundation Medicine, Inc. is a molecular information company, which engages in the provision of information on clinical treatment decisions for patients with cancer. Its products includes: FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers; FoundationACT; and FoundationFocus CDxBRCA.